Merck Receives Positive EU CHMP Opinion for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Infections Due to Aerobic Gram-Negative Organisms in Adults with Limited Treatment Options
Dateline City:
KENILWORTH, N.J.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending RECARBRIO™ (imipenem, cilastatin, and relebactam), a new combination antibacterial agent, for approval. If approved by the European Commission, RECARBRIO would be indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
Language:
English
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
